其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Pempidine CAS Registry Number: 79-55-0 五甲基哌啶

CAS Name: 1,2,2,6,6-Pentamethylpiperidine
Percent Composition: C 77.35%, H 13.63%, N 9.02%
Literature References: Ganglion blocking agent. Prepn by methylation of 2,2,6,6-tetramethylpiperidine: Leonard, Hauck, J. Am. Chem. Soc. 79, 5289 (1957); Hall, ibid. 5447. Description: Spinks, Young, Nature 181, 1397 (1958); Lee et al., ibid. 1717.

Pentacynium Bis(methylsulfate) CAS Registry Number: 3810-83-1 4-{2-[(5-氰-5,5-二苯基戊基)(二甲基氨基]乙基}-4-甲基吗啡烯-4-铵(硫酸甲酯)

CAS Name: 4-[2-[(5-Cyano-5,5-diphenylpentyl)dimethylammonio]ethyl]-4-methylmorpholinium bis(methylsulfate)
Additional Names: N1-(5-cyano-5,5-diphenylpentyl)-N1,N1,N2-trimethylethylene-1-ammoniu...
Literature References: Ganglionic blocker. Prepn: Billinghurst, US 2851458 (1958 to Burroughs Wellcome).

Plegatil CAS Registry Number: 53597-29-8

CAS Name: N,N-Diethyl-N-methyl-2-[2-(trimethylammonio)ethoxy]-1-propanaminium diiodide
Additional Names: N,N-diethyl-N,N',N',N'-tetramethyl-N,N'-(2-methyl-3-oxapentamethylene)bis[ammonium iodid...
Literature References: Ganglionic blocking agent. Prepd but not claimed: G. Pakleppa, D. Lenke, DD 11363 (1956), C.A. 53, 2094i (1959). Pharmacology: D. Lenke, Arzneim.-Forsch. 7, 616 (1957); ibid. 11, 571 (1961).

tert-Amyl Methyl Ether CAS Registry Number: 994-05-8 甲基叔戊基醚

CAS Name: 2-Methoxy-2-methylbutane
Additional Names: methyl tert-pentyl ether; 1,1-dimethylpropyl methyl ether; methyl tert-amyl ether; TAME
Percent Composition: C 70.53%, H 13.81%, O 15.66%
Literature References: Gasoline octane booster. Prepn: A. Reychler, Bull. Soc. Chim. Belg. 21, 71 (1907); and properties: T. W. Evans, K. R. Edlund, Ind. Eng. Chem. 28, 1186 (1936). Industrial synthesis and processing: H. Short, Chem. Eng. 93, 34 (1986); S. Randriamahefa et al., J. Mol. Catal. 49, 85 (1988); W. J. Reagan, Prepr. Pap. - Am. Chem. Soc. Div. Fuel Chem. 39, 337 (1994). Reaction equilibria in synthesis: L. K. Rihko et al., J. Chem. Eng. Data 39, 700 (1994). Chromatographic and spectroscopic analyses: J. S. Hardman et al., Fuel 72, 1563 (1993). Comparison with MTBE, q.v., of effects on emissions: W. J. Koehl et al., Soc. Automot. Eng. SP-1000, vol 2, 289 (1993). Reaction with nitrate radical (environmental implications): S. Langer, E. Ljungström, J. Phys. Chem. 98, 5906 (1994).

Irsogladine CAS Registry Number: 57381-26-7 伊索拉定

CAS Name: 6-(2,5-Dichlorophenyl)-1,3,5-triazine-2,4-diamine
Additional Names: 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine; dicloguamine
Percent Composition: C 42.21%, H 2.76%, Cl 27.69%, N...
Literature References: Gastric cytoprotectant with benzoguanamine skeleton. Prepn: H. Murai et al., DE 2506814; eidem, US 3966728 (1975, 1976 both to Nippon Shinyaku). Series of articles on pharmacology: F. Ueda et al., Arzneim.-Forsch. 34, 474-491 (1984). Tissue distribution studies: T. Ando et al., ibid. 36, 1221 (1984). Metabolism: M. Sugiyama et al., ibid. 1229. Phase I study: M. Nakashima et al., ibid. 34, 492 (1984). Mechanism of antiulcer action study: F. Ueda et al., Oyo Yakuri 33, 157 (1987), C.A. 107, 17604a (1987).

Rebamipide CAS Registry Number: 90098-04-7 瑞巴派特

CAS Name: a-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic acid
Additional Names: (±)-a-(p-chlorobenzamido)-1,2-dihydro-2-oxo-4-quinolinepropionic acid; 2-(4-chlorobenzoyl...
Literature References: Gastric cytoprotectant. Prepn: M. Uchida et al., DE 3324034; eidem, US 4578381; (1984, 1986 both to Otsuka). Synthesis and pharmacology: M. Uchida et al., Chem. Pharm. Bull. 33, 3775 (1985); of enantiomers: eidem, ibid. 35, 853 (1987). Antiulcer activity in rats: K. Yamasaki et al., Eur. J. Pharmacol. 142, 23 (1987); K. Yamasaki et al., Jpn. J. Pharmacol. 49, 441 (1989). HPLC determn in plasma and urine: Y. Shioya, T. Shimizu, J. Chromatogr. 434, 283 (1988).

Pantoprazole CAS Registry Number: 102625-70-7 泮托拉唑

CAS Name: 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolePercent Composition: C 50.13%, H 3.94%, F 9.91%, N 10.96%, O 16.69%, S 8.36%
Literature References: Gastric proton pump inhibitor. Prepn: B. Kohl et al., EP 166287; eidem, US 4758579 (1986, 1988 both to Byk Gulden); eidem, J. Med. Chem. 35, 1049 (1992). Mechanism of action: W. A. Simon et al., Biochem. Pharmacol. 39, 1799 (1990). HPLC determn in plasma and serum: R. Huber et al., J. Chromatogr. 529, 389 (1990). Clinical pharmacokinetics: B. Simon et al., Z. Gastroenterol. 28, 443 (1990). Clinical trial in duodenal ulcer: P. Müller et al., ibid. 30, 771 (1992); in Zollinger-Ellison syndrome: E. A. Lew et al., Gastroenterology 118, 696 (2000). Review of pharmacology and clinical experience: P. Poole, Am. J. Health-Syst. Pharm. 58, 999-1008 (2001).

Revaprazan CAS Registry Number: 199463-33-7 盐酸瑞伐拉赞

CAS Name: 4-(3,4-Dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-2-pyrimidinamine
Additional Names: 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoq...
Literature References: Gastric proton pump inhibitor. Prepn: J. W. Lee et al., WO 9605177; eidem, US 5750531 (1996, 1998 both to Yuhan). HPLC determn in plasma and urine: K. S. Han et al., J. Chromatogr. B 696, 312 (1997). Clinical pharmacokinetics: K.-S. Yu et al., J. Clin. Pharmacol. 44, 73 (2004).

Lansoprazole CAS Registry Number: 103577-45-3 兰索拉唑

CAS Name: 2-[[[3-Methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
Additional Names: 2-(2-benzimidazolylsulfinylmethyl)-3-methyl-4-(2,2,2-trifluoroethoxy)pyridineT...
Literature References: Gastric proton-pump inhibitor. Prepn: A. Nohara, Y. Maki, EP 174726; eidem, US 4628098 (both 1986 to Takeda). HPLC determn in plasma: T. Uno et al., J. Chromatogr. B 816, 309 (2005). Pharmacology: H. Satoh et al., J. Pharmacol. Exp. Ther. 248, 806 (1989). Mechanism of action study: H. Nagaya et al., ibid. 252, 1289 (1990). Clinical pharmacology and effect on human gastric acid secretion: P. Müller et al., Aliment. Pharmacol. Ther. 3, 193 (1989). Review of pharmacology and clinical experience: H. D. Langtry, M. I. Wilde, Drugs 54, 473-500 (1997). Comparative clinical trial with esomeprazole in erosive esophagitis: C. W. Howden et al., Clin. Drug Invest. 22, 99 (2002).

Omeprazole CAS Registry Number: 73590-58-6 奥美拉唑

CAS Name: 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazoleTrademarks: Gastrogard (Merial); Losec (AstraZeneca); Mopral (AstraZeneca); OmeLich (Winthrop); Omelind...
Literature References: Gastric proton-pump inhibitor. Prepn: U. K. Junggren, S. E. Sjostrand, EP 5129; eidem, US 4255431 (1979, 1981 both to AB Hässle). Resolution and activity of enantiomers: P. Erlandsson et al., J. Chromatogr. 532, 305 (1990). Manuf process for optically pure salts: S. Von Unge, US 5693818 (1997 to Astra). Pharmacology: P. Muller et al., Arzneim.-Forsch. 33, 1685 (1983). Mechanism of action study: B. Wallmark et al., Biochim. Biophys. Acta 778, 549 (1984). LC determn in plasma and urine: P. Lagerstrom, B. Persson, J. Chromatogr. 309, 347 (1984). Survey of preclinical data: Scand. J. Gastroenterol. 20, Suppl 108, 1-120 (1985). Toxicological studies: L. Ekman et al., ibid. 53. Clinical trial in Zollinger-Ellison syndrome: C. B. H. W. Lamers et al., N. Engl. J. Med. 310, 758 (1984); in duodenal ulcer: K. Lauritsen et al., ibid. 312, 958 (1985). Veterinary trial in race horses: M. J. Murray et al., Equine Vet. J. 29, 425 (1997). Review of pharmacology and clinical efficacy: H. D. Langtry, M. I. Wilde, Drugs 56, 447-486 (1998).